High-dose glucocorticoids increase serum levels of soluble IL-6 receptor α and its ratio to soluble gp130: An additional mechanism for early increased bone resorption

European Journal of Endocrinology

Volumn 154, Issue 5, 2006, Pages 745-751

  Dovio, Andrea ^a   Perazzolo, Laura ^a   Saba, Laura ^a   Termine, Angela ^a   Capobianco, Marco ^a   Bertolotto, Antonio ^a   Angeli, Alberto ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CARBOXY TERMINAL TELOPEPTIDE; GLYCOPROTEIN; GLYCOPROTEIN GP 130; GLYCOPROTEIN GP80; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 6 RECEPTOR ALPHA; METHYLPREDNISOLONE; OSTEOCALCIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CORTICOSTEROID INDUCED OSTEOPOROSIS; DOSE RESPONSE; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IN VITRO STUDY; INDIVIDUALIZATION; MALE; MICROENVIRONMENT; MULTIPLE SCLEROSIS; OSTEOCLAST; OSTEOLYSIS; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEPTOR UPREGULATION; RELAPSE; SHORT COURSE THERAPY; SIGNAL TRANSDUCTION;

ADULT; BIOLOGICAL MARKERS; BONE RESORPTION; CALCIUM; CYTOKINE RECEPTOR GP130; FEMALE; GLUCOCORTICOIDS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; OSTEOCLASTS; PHOSPHORUS; PREDNISOLONE; RECEPTORS, INTERLEUKIN-6; SOLUBILITY; VITAMIN D;

EID: 33744538918     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.02147     Document Type: Article

References (38)

1. Canalis E, Bilezikian JP, Angeli A & Giustina A. Perspectives on glucocorticoid-induced osteoporosis. Bone 2004 34 593-598.
2. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B & Cooper C. Use of oral corticosteroids and risk of fractures. Journal of Bone and Mineral Research 2000 15 993-1000.
3. Weinstein RS, Chen JR, Powers CC, Stewart SA, Landes RD, Bellido T, Jilka RL, Parfitt AM & Manolagas SC. Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. Journal of Clinical Investigation 2002 109 1041-1048.
4. Beavan S, Horner A, Bord S, Ireland D & Compston J. Colocalization of glucocorticoid and mineralocorticoid receptors in human bone. Journal of Bone and Mineral Research 2001 16 1496-1504.
5. Bland R. Steroid hormone receptor expression and action in bone. Clinical Science 2000 98 217-240.
6. Patschan D, Loddenkemper K & Buttgereit F. Molecular mechanisms of glucocorticoid-induced osteoporosis. Bone 2001 29 498-505.
7. Hofbauer LC, Kuhne CA & Viereck V. The OPG/RANKL/RANK system in metabolic bone diseases. Journal of Musculoskeletal Neuronal Interactions 2004 4 268-275.
8. Wong PK, Campbell IK, Egan PJ, Ernst M & Wicks IP. The role of the intcrleukin-6 family of cytokines in inflammatory arthritis and bone turnover. Arthritis & Rheumatism 2003 48 1177-1189.
9. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G & Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochemical Journal 2003 374 1-20.
10. Udagawa N, Takahashi N, Katagiri T, Tamura T, Wada S, Findlay DM, Martin TJ, Hirota H, Taga T, Kishimoto T & Suda T. Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors. Journal of Experimental Medicine 1995 182 1461-1468.
11. Palmqvist P, Persson E, Conaway HH & Lerner UH. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae. Journal of Immunology 2002 169 3353-3362.
12. O'Brien CA, Gubrij I, Lin SC, Saylors RL & Manolagas SC. STAT3 activation in stromal/osteoblastic cells is required for induction of the receptor activator of NF-kappaB ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1,2 5-dihydroxyvitamin D3 or parathyroid hormone. Journal of Biological Chemistry 1999 274 19301-19308.
13. Hofbauer LC, Lacey DL, Dunstan CR, Spelsberg TC, Riggs BL & Khosla S. Interleukin-1 beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 1999 25 255-259.
14. Castellino AM & Chao MV. Trans-signaling by cytokine and growth factor receptors. Cytokine Growth Factor Reviews 1996 7 297-302.
15. Kamimura D, Ishihara K & Hirano T. IL-6 signal transduction and its physiological roles: the signal orchestration model. Reviews of Physiology, Biochemistry and Pharmacology 2003 149 1-38.
16. Lin SC, O'Brien CA & Manolagas SC. Sex steroids decrease and glucocorticoids increase the levels of gp130 protein in bone marrow-derived stromal cells: correlation with altered IL-6 induced DNA-binding activity of Statl and Stat3 complexes. Journal of Bone and Mineral Research 1996 11 S161 (abstrct).
17. Richards CD, Langdon C, Deschamps P, Pennica D & Shaughnessy SG. Stimulation of osteoclast differentiation in vitro by mouse oncostatin M, leukaemia inhibitory factor, cardiotrophin-1 and interleukin 6: synergy with dexamethasone. Cytokine 2000 12 613-621.
18. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH & Tourtellotte WW. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Annals of Neurology 1983 13 227-231.
19. Ton FN, Gunawardene SC, Lee H & Neer RM. Effects of low-dose prednisone on bone metabolism. Journal of Bone and Mineral Research 2005 20 464-470.
20. Dovio A, Perazzolo L, Osella G, Ventura M, Termine A, Milano E, Bertolotto A & Angeli A. Immediate fall of bone formation and transient increase of bone resorption in the course of high-dose, short-term glucocorticoid therapy in young patients with multiple sclerosis. Journal of Clinical Endocrinology and Metabolism 2004 89 4923-4928.
21. Fujita T, Satomura A, Hidaka M, Ohsawa I, Endo M & Ohi H. Acute alteration in bone mineral density and biochemical markers for bone metabolism in nephrotic patients receiving high-dose glucocorticoid and one-cycle etidronate therapy. Calcified Tissue International 2000 66 195-199.
22. Godschalk MF & Downs RW. Effect of short-term glucocorticoids on serum osteocalcin in healthy young men. Journal of Bone and Mineral Research 1988 3 113-115.
23. Nielsen HK, Charles P & Mosekilde L. The effect of single oral doses of prednisone on the circadian rhythm of serum osteocalcin in normal subjects. Journal of Clinical Endocrinology and Metabolism 1988 67 1025-1030.
24. Prummel MF, Wiersinga WM, Lips P, Sanders GT & Sauerwein HP. The course of biochemical parameters of bone turnover during treatment with corticosteroids. Journal of Clinical Endocrinology and Metabolism 1991 72 382-386.
25. Pearce G, Tabensky DA, Delmas PD, Baker HW & Seeman E. Corticosteroid-induced bone loss in men. Journal of Clinical Endocrinology and Metabolism 1998 83 801-806.
26. Paglia F, Dionisi S, De Geronimo S, Rosso R, Romagnoli E, Raejntroph N, Ragno A, Celi M, Pepe J, D'Erasmo E & Minisola S. Biomarkers of bone turnover after a short period of steroid therapy in elderly men. Clinical Chemistry 2001 47 1314-1316.
27. Ardissone P, Rota E, Durelli L, Limone P & Isaia GC. Effects of high doses of corticosteroids on bone metabolism. Journal of Endocrinological Investigation 2002 25 129-133.
28. Sasaki N, Kusano E, Ando Y, Nemoto J, Iimura O, Ito C, Takeda S, Yano K, Tsuda E & Asano Y. Changes in osteoprotegerin and markers of bone metabolism during glucocorticoid treatment in patients with chronic glomerulonephritis. Bone 2002 30 853-858.
29. Rubin MR & Bilezikian JP. Clinical review 151: The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: a re-examination of the evidence. Journal of Clinical Endocrinology and Metabolism 2002 87 4033-4041.
30. Bonadonna S, Burattin A, Nuzzo M, Bugari G, Rosei EA, Valle D, Iori N, Bilezikian JP, Veldhuis JD & Giustina A. Chronic glucocorticoid treatment alters spontaneous pulsatile parathyroid hormone secretory dynamics in human subjects. European Journal of Endocrinology 2005 152 199-205.
31. Gao Y, Morita I, Maruo N, Kubota T, Murota S & Aso T. Expression of IL-6 receptor and gp130 in mouse bone marrow cells during osteoclast differentiation. Bone 1998 22 487-493.
32. Polgar A, Brozik M, Toth S, Holub M & Falus A. A synthetic corticosteroid, dexamethasone regulates generation of soluble form of interleukin-6 receptor of human lymphocytes, in vitro. Acta Biologica Hungarica 2002 53 307-315.
33. Geisterfer M, Richards CD & Gauldie J. Cytokines oncostatin M and interleukin 1 regulate the expression of the IL-6 receptor (gp80, gp130). Cytokine 1995 7 503-509.
34. Vermes C, Jacobs JJ, Zhang J, Firneisz G, Roebuck KA & Glant TT. Shedding of the interleukin-6 (IL-6) receptor (gp80) determines the ability of IL-6 to induce gp130 phosphorylation in human ostcoblasts. Journal of Biological Chemistry 2002 277 16879-16887.
35. O'Brien CA, Jia D, Plotkin LI, Bellido T, Powers CC, Stewart SA, Manolagas SC & Weinstein RS. Glucocorticoids act directly on ostcoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 2004 145 1835-1841.
36. Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Hashimoto J & Kishimoto T. Long-term safety and efficacy of anti-interleukin 6 receptor antibody (MRA) in patients with rheumatoid arthritis. Arthritis, Rheumatism 2003 9 (Suppl) S126 (abstract).
37. Yokota S, Miyamae T, Imagawa T, Iwata N, Katakura S, Mori M, Nishimoto N, Yoshizaki K, Woo P, Hirsch R & Kishimoto T. Phase II trial of anti-IL-6 receptor antibody (MRA) for children with systemic-onset juvenile idipathic arthritis. Arthritis & Rheumatism 2003 9 (Suppl) S429 (abstract).
38. Lisignoli G, Piacentini A, Toneguzzi S, Grassi F, Cocchini B, Ferruzzi A, Gualtieri G & Facchini A. Osteoblasts and stromal cells isolated from femora in rheumatoid arthritis (RA) and ostcoarthritis (OA) patients express IL-11, leukaemia inhibitory factor and oncostatin M. Clinical and Experimental Immunology 2000 119 346-353.